Clinical Scorecard: Collaborative Global Efforts in Addressing Temporary Mechanical Circulatory Support for Fulminant Myocarditis
At a Glance
Category
Detail
Condition
Fulminant Myocarditis
Key Mechanisms
Severely impaired left ventricular ejection fraction (LVEF < 40%), need for inotropes and/or temporary mechanical circulatory support (t-MCS) as per source.
Target Population
Critically ill patients with fulminant myocarditis.
Care Setting
ICU and high-volume ECMO centers.
Key Highlights
t-MCS technologies include VA-ECMO, IABP, and percutaneous ventricular assist devices.
One-year mortality in the cohort was 36%; ensure source citation for accuracy.
VA-ECMO was the dominant t-MCS strategy, used in nearly two-thirds of patients.
31% of cases were diagnosed on clinical grounds alone, highlighting a diagnostic gap.
Fewer than half of the cohort received immunomodulation, with unclear efficacy and safety.
Guideline-Based Recommendations
Diagnosis
Clear exclusion criteria and systematic case ascertainment should be applied.
Management
Careful patient selection and expert management are essential due to the risks associated with t-MCS.
Monitoring & Follow-up
Long-term outcomes should be assessed, focusing on mortality, heart transplantation, or LVAD, including specific metrics.
Risks
Substantial risks include bleeding, limb ischemia, hemolysis, infection, and stroke.
Patient & Prescribing Data
Patients with fulminant myocarditis requiring t-MCS.
The timing and indications for immunotherapy remain unresolved; clarify based on source.
Clinical Best Practices
Utilize coordinated multicenter data for standardized diagnostic and outcome definitions, with specific examples.
Consider the timing of biopsies, as those performed > 2 days after admission are associated with worse outcomes.
